Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a natural alcohol byproduct calm withdrawal? hospital trial tests IV acetate

NCT ID NCT07810946

Symptom relief Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Alcohol withdrawal affects many hospitalized patients and standard sedative treatments have serious side effects. Researchers at the University of Colorado are testing whether intravenous sodium acetate, a natural byproduct of alcohol that the brain can use as fuel, is safe and practical to give alongside usual care. The trial enrolls 75 adults hospitalized for alcohol withdrawal and measures how many agree to join, how well the infusion is tolerated, and how much sedative medication patients need.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intravenous sodium acetate, a salt of a natural alcohol byproduct used as an alternative brain fuel
What this could lead to
If it works, intravenous acetate could give hospitals a new way to ease alcohol withdrawal and cut reliance on sedatives that carry serious side effects.
What could go wrong
This is an early-stage safety and feasibility study in 75 people, so it cannot prove the treatment works. Acetate infusions can disturb acid balance and fluid levels, and the results may not apply to all patients with alcohol withdrawal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active treatment for alcohol withdrawal (e.g. use of protocolized order set in an inpatient setting) * Inpatient admission ordered * Adult \> 21 years old Exclusion Criteria: * End-stage renal disease or likely need for renal replacement therapy in the next 12 hours * Heart failure with reduced ejection fraction (\<30%) * Receipt of \>2L crystalloids prior to randomization * Advanced liver disease (Child's C or D) * Uncontrolled mental health condition * \>24 hours since ED arrival * Pregnant or incarcerated * Unable to consent and/or no proxy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol abstinence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alcohol Abstinence alcohol abuse alcohol withdrawal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol abstinence Alcohol use disorder Alcohol withdrawal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Colorado, Anshcutz Medical Campus

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.